🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Le Groupe consultatif HEMA choisit son premier sujet de recherche : Évaluer les bienfaits à prendre en considération dans la prise de décisions en ETS. 👉 cda-amc.ca/fr/nouvelles/l…

We've joined ICER and NICE to select the first research topic for the Health Economics Methods Advisory group: an assessment of the benefits of treatment that are appropriate to consider in #HTA decision-making. 👉 cda-amc.ca/news/health-ec…

⚠️Call for Patient and Clinician Input⚠️ We are requesting input on pegunigalsidase alfa for Fabry disease. Deadline is March 31, 2025: cda-amc.ca/pegunigalsidas… #HTA --- ⚠️Appel d’observations, patients et cliniciens⚠️ Nous sollicitons des observations sur le pégunigalsidase alfa

⚠️Call for Patient and Clinician Input⚠️ We are requesting input on asciminib (#Scemblix) for Philadelphia chromosome-positive chronic myeloid leukemia. Deadline is March 24, 2025: cda-amc.ca/asciminib-0 #HTA --- Appel d’observations, patients et cliniciens ⚠️ Nous sollicitons

⚠️Call for Patient and Clinician Input⚠️ We are requesting input on glofitamab (#Columvi) for relapsed or refractory diffuse large B-cell lymphoma. Deadline is March 24, 2025: cda-amc.ca/glofitamab-0 #HTA --- Appel d’observations, patients et cliniciens ⚠️ Nous sollicitons des

⚠️Call for Patient and Clinician Input⚠️ We are requesting input on risperidone (#Okedi) for schizophrenia in adults. Deadline is March 31, 2025: cda-amc.ca/risperidone-1 #HTA --- ⚠️Appel d’observations, patients et cliniciens⚠️ Nous sollicitons des observations sur la

⚠️Call for Patient and Clinician Input⚠️ We are requesting input on pembrolizumab (#Keytruda) for head and neck squamous cell carcinoma. Deadline is March 31, 2025: cda-amc.ca/pembrolizumab-… #HTA --- ⚠️Appel d’observations, patients et cliniciens ⚠️ Nous sollicitons des

⚠️Call for Patient and Clinician Input⚠️ We are requesting input on risankizumab (#Skyrizi) for ulcerative colitis. Deadline is April 11, 2025: cda-amc.ca/risankizumab-1 #HTA --- ⚠️Appel d’observations, patients et cliniciens⚠️ Nous sollicitons des observations sur le risankizumab

⚠️Call for Patient and Clinician Input⚠️ We are requesting input on talazoparib (#Talzenna) for metastatic castration-resistant prostate cancer. Deadline is April 7, 2025: cda-amc.ca/talazoparib-1 #HTA --- ⚠️Appel d’observations, patients et cliniciens⚠️ Nous sollicitons des

⚠️Call for Patient and Clinician Input⚠️ We are requesting input on nivolumab and ipilimumab (#Opdivo and #Yervoy) for unresectable or metastatic MSI-H or dMMR colorectal cancer. Deadline is April 7, 2025: cda-amc.ca/nivolumab-and-… #HTA --- ⚠️Appel d’observations, patients et

⚠️Call for Patient and Clinician Input⚠️ We are requesting input on acalabrutinib (#Calquence) for mantle cell lymphoma (#MCL). Deadline is April 7, 2025: cda-amc.ca/acalabrutinib #HTA --- Appel d’observations, patients et cliniciens ⚠️ Nous sollicitons des observations sur

⚠️Call for Patient and Clinician Input⚠️ We are requesting input on pembrolizumab (#Keytruda) for cervical cancer. Deadline is April 7, 2025: cda-amc.ca/pembrolizumab-… #HTA --- Appel d’observations, patients et cliniciens ⚠️ Nous sollicitons des observations sur le pembrolizumab

À l’avenir, nous délaisserons X pour communiquer avec vous par le biais d’autres plateformes. Nous vous remercions de votre soutien et de votre engagement ici. Retrouvons-nous sur : LinkedIn : linkedin.com/company/cda-amc Facebook : facebook.com/cda.amc Instagram :